Core Viewpoint - The company has observed a significant increase in its share price and trading volume on specific dates in late October and early November 2025, but the board is unaware of any reasons for these changes or any undisclosed information that could affect the market [1] Group 1 - The board confirmed that the company's business operations remain normal and that there have been no significant changes in its financial condition as of the date of the announcement [1] - A wholly-owned subsidiary of the company, Shanxi Tuo Yun Biotechnology Co., Ltd., signed a strategic cooperation agreement on October 23, 2025, with three other companies for a procurement deal [1] - The strategic cooperation agreement involves a sales consortium purchasing no less than RMB 1 billion (approximately 140 million USD) worth of Rhizoclonium and related products from Shanxi Tuo Yun during the period from 2026 to 2028 [1]
透云生物 (01332) 回应股价异动 全资附属签 10 亿元莱茵衣藻采购框架协议